Stability and biological testing of taurine-conjugated bile acid antioxidant microcapsules for diabetes treatment. (6th February 2019)

• Record Type: Journal Article
• Authors: Mooranian, Armin; Zamani, Nassim; Mikov, Momir; Goločorbin-Kon, Svetlana; Stojanovic, Goran; Arfuso, Frank; Al-Salami, Hani
• Is Part Of: Therapeutic delivery. Volume 10:Number 2(2019)
• Page Start: 99
• Page End: 106
• Publication Date: 2019-02-06
• Subjects: diabetes mellitus -- eudragit -- microencapsulation -- oral delivery -- probucol -- taurocholic acid; Drug delivery systems -- Periodicals; Therapeutics -- Periodicals; 615.6
• DOI: 10.4155/tde-2018-0034
• Languages: English
• ISSNs: 2041-5990

Abstract

Aim: Taurine-conjugated bile acids possess positive formulation-stabilization effects, which are desirable in diabetes treatments. The taurine-conjugated bile acid, taurocholic acid (TCA), has shown promising formulation-stabilizing effects on the delivery of the antioxidant drug, probucol (PB), but success is limited due to its poor release profile. This study aimed to design new PB-TCA formulations using new polymers, and examine antioxidant and antidiabetic effects using β-cells for PB with or without TCA.Materials and methods: Different formulations using alginate-insoluble esters of polymethylacrylate polymers encapsulating PB and TCA were developed, microencapsulated and examined for stability and biological activity.Results: TCA addition to new PB matrices improved osmotic and mechanical properties, and this effect was dependent on polymethylacrylate composition and concentration.Conclusion: TCA can optimize the oral delivery of anti-diabetic compounds.